A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

  • STATUS
    Recruiting
  • participants needed
    108
  • sponsor
    Genentech, Inc.
Send
Updated on 16 February 2024
See if I qualify
solid tumour
solid tumor
kras
metastatic malignant solid tumor
ki-ras
kras g12c mutation

Summary

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

Details
Condition Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Colorectal Cancer, Rectal disorder, Advanced Solid Tumors
Age 18years - 100years
Treatment GDC-6036
Clinical Study IdentifierNCT04449874
SponsorGenentech, Inc.
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation

Exclusion Criteria

Active brain metastases
Malabsorption or other condition that interferes with enteral absorption
Clinically significant cardiovascular dysfunction or liver disease
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

solid tumour
solid tumor
kras
metastatic malignant solid tumor
ki-ras
kras g12c mutation

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.